Peter Johannes Holst

Peter Johannes Holst

Guest Researcher

Member of:

  • EXPVACC/LEV team

ORCID: 0000-0002-1279-304X

Publication year:
All
1 - 3 out of 3Page size: 10
  1. 2020
  2. Published

    Cancer associated endogenous retroviruses: Ideal immune targets for adenovirus-based immunotherapy

    Bermejo, A. V., Ragonnaud, Emeline, Daradoumis, J. & Holst, Peter Johannes, 2020, In: International Journal of Molecular Sciences. 21, 14, p. 1-21 21 p., 4843.

    Research output: Contribution to journal › Review › Research › peer-review

  3. Published

    MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans

    Esposito, I., Cicconi, P., D'Alise, A. M., Brown, A., Esposito, M., Swadling, L., Holst, P. J., Bassi, M. R., Stornaiuolo, M., Mori, F., Vassilev, V., Li, W., Donnison, T., Gentile, C., Turner, B., von Delft, A., Del Sorbo, M., Barra, F., Contino, A. M., Abbate, A. & 15 others, Novellino, E., Thomsen, Allan Randrup, Christensen, Jan Pravsgaard, Lahm, A., Grazioli, F., Ammendola, V., Siani, L., Colloca, S., Klenerman, P., Nicosia, A., Dorrell, L., Folgori, A., Capone, S., Barnes, E. & PEACHI Consortium, P. C., 2020, In: Science Translational Medicine. 12, 548, eaaz7715.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    The potential of adenoviral vaccine vectors with altered antigen presentation capabilities

    Neukirch, L., Fougeroux, Cyrielle Elyette, Andersson, A. M. C. & Holst, Peter Johannes, 2020, In: Expert Review of Vaccines. 19, 1, p. 25-41

    Research output: Contribution to journal › Review › Research › peer-review

ID: 7853